Attached files

file filename
EX-99.1 - PRESS RELEASE DATED APRIL 4, 2017 - NeuBase Therapeutics, Inc.ex99-1.htm
EX-10.1 - FORM OF SECURITIES PURCHASE AGREEMENT - NeuBase Therapeutics, Inc.ex10-1.htm
EX-4.1 - FORM OF WARRANT - NeuBase Therapeutics, Inc.ex4-1.htm

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

 

 

 

FORM 8-K 

 

Current Report 

Pursuant to Section 13 or 15(d) of the 

Securities Exchange Act of 1934 

 

Date of report (Date of earliest event reported): April 4, 2017 

 

Ohr Pharmaceutical, Inc.

 (Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware   333-88480   46-5622433
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)

 

800 Third Avenue, 11th Floor, New York, NY 10022
(Address of Principal Executive Offices) (Zip Code)

 

(212) 682-8452
(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

 

 
 

 

Item 8.01Other Events.

 

On April 4, 2017, Ohr Pharmaceutical, Inc. issued a press release announcing that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits: 

 

4.1Form of Warrant

 

10.1Form of Securities Purchase Agreement

 

99.1Press Release dated April 4, 2017

 

 
 

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OHR PHARMACEUTICAL, INC.
  (Registrant)
     
Date:    April 4, 2017 By: /s/ Sam Backenroth
    Sam Backenroth
    Chief Financial Officer

 

 
 

 

EXHIBIT INDEX
       
Exhibit No.   Description  
       
4.1   Form of Warrant  
       
10.1   Form of Securities Purchase Agreement
       
99.1   Press Release dated April 4, 2017